Ahmad Awada

Ahmad Awada's AcademicInfluence.com Rankings

Ahmad Awada

Computer Science

#8016

Historical Rank

Machine Learning

#2901

Historical Rank

Artificial Intelligence

#3206

Historical Rank

Database

#4845

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Ahmad Awada Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ahmad Awada's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. (2007) (1477)
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. (2005) (855)
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. (2010) (503)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study (2019) (464)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (396)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. (2007) (392)
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. (2000) (352)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane (2015) (347)
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours (2005) (329)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. (2012) (325)
Review: side effects of approved molecular targeted therapies in solid cancers. (2007) (312)
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. (2013) (305)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. (2018) (297)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019) (266)
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. (2016) (246)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. (2016) (225)
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. (2014) (221)
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. (2010) (205)
Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer (2006) (185)
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies (2014) (172)
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? (2006) (169)
Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation (2006) (165)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. (2012) (161)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (2020) (158)
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (2015) (158)
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. (1997) (155)
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2006) (152)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. (2008) (150)
Streptococcal and enterococcal bacteremia in patients with cancer. (1992) (147)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. (2018) (144)
Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials (2008) (140)
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. (1994) (138)
LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 (2017) (137)
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. (2013) (137)
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (2017) (127)
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. (2001) (120)
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. (2003) (116)
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. (2010) (113)
Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) (2017) (111)
Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy (2003) (109)
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. (2013) (108)
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. (2009) (108)
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. (2008) (100)
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. (2002) (93)
Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial: (2016) (92)
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer (2011) (92)
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. (2009) (89)
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). (2006) (87)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. (2004) (82)
Novel cytotoxic drugs: old challenges, new solutions. (2008) (80)
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. (2008) (80)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (2012) (77)
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies (2017) (76)
High serum galectin‐3 in advanced melanoma: preliminary results (2006) (75)
Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer (2017) (74)
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. (2009) (71)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer (2012) (71)
Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. (2012) (70)
The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies (2008) (70)
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. (2015) (70)
Current management of ovarian carcinosarcoma (2006) (66)
Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes (2012) (65)
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. (2013) (65)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer (2020) (63)
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer (2016) (62)
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. (2016) (61)
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (2014) (60)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. (2011) (59)
Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art (2017) (56)
Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. (2010) (55)
Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome (2014) (55)
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). (2008) (54)
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. (2004) (53)
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. (2002) (52)
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients (2009) (52)
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. (2016) (50)
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (2014) (50)
Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. (2011) (50)
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. (2018) (49)
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? (2012) (49)
TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome (2011) (48)
Molecular targeted therapies in breast cancer: where are we now? (2007) (48)
Febrile neutropenia: a critical review of the initial management. (2011) (48)
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer (2016) (47)
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial (2015) (47)
Molecular-targeted therapies: lessons from years of clinical development. (2008) (45)
Phase II study of E7070 in patients with metastatic melanoma. (2005) (45)
Abstract P3-14-01: A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results (2010) (45)
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study (2008) (45)
A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors (2001) (44)
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients (2009) (44)
Faculty Opinions recommendation of Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. (2019) (43)
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion (1994) (42)
Molecular profiling of head and neck tumors (2004) (42)
Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. (2016) (41)
Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. (2006) (40)
First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. (2010) (40)
Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges (2013) (40)
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer (2016) (40)
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. (2017) (39)
Novel treatment strategies for malignant melanoma: a new beginning? (2007) (38)
Learning from the "tsunami" of immune checkpoint inhibitors in 2015. (2016) (38)
Novel treatment strategies for soft tissue sarcoma. (2007) (37)
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study (2016) (37)
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery. (2007) (37)
Is VEGF a predictive biomarker to anti-angiogenic therapy? (2011) (36)
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours (2020) (36)
Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives (2018) (35)
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (35)
Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). (2011) (35)
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types (2017) (34)
New Drug Combination Strategies in Melanoma: Current Status and Future Directions. (2017) (34)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) (2000) (34)
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? (2008) (33)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (2020) (33)
Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors (2005) (33)
Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer (2003) (33)
“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy (2015) (33)
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. (1995) (32)
Primary chemotherapy for breast cancer: the evidence and the future. (2004) (31)
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors (2012) (31)
New drug development (2012) (31)
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies (2017) (31)
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement (2012) (30)
Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). (2004) (29)
Papillary fibroelastoma of mitral valve chorda. (1993) (29)
Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. (2016) (29)
PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial (2015) (29)
Oncological care organisation during COVID-19 outbreak (2020) (28)
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). (2011) (28)
Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. (2001) (28)
Targeted therapies of solid cancers: new options, new challenges (2013) (27)
Monoclonal Antibody-Based Targeted Therapy in Breast Cancer (2012) (27)
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma (2010) (27)
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy (2009) (26)
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. (2021) (26)
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors (2013) (26)
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors (2016) (26)
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma (2015) (26)
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. (2006) (25)
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. (2019) (25)
Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer (2016) (25)
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial (2010) (25)
Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors (2001) (25)
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. (2012) (25)
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients (2009) (25)
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors (2019) (25)
Management of Head and Neck Cancer in Elderly Patients (2009) (24)
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. (2016) (24)
Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? (2011) (24)
Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. (2013) (24)
Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study (2008) (23)
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients (2013) (23)
A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). (2019) (23)
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. (2014) (23)
The hallmarks of cancer revisited (2012) (22)
Faculty Opinions recommendation of Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. (2019) (22)
Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations (2016) (22)
Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature (2017) (22)
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. (2013) (22)
Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine. (2014) (22)
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. (2012) (22)
A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors (2016) (22)
Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? (2007) (22)
Management of Cutaneous Locoregional Recurrences of Melanoma: A New Therapeutic Perspective with Imiquimod (2003) (21)
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). (2012) (21)
Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. (2011) (21)
Risk factors for the development of brain metastases in patients with HER2-positive breast cancer (2018) (21)
Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology (2012) (21)
Absence status: an overlooked cause of acute confusion in hemodialysis patients. (1998) (20)
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity (2015) (20)
Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial (2011) (20)
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer (2020) (20)
Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer (2016) (20)
Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol (2018) (20)
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (2013) (20)
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. (2018) (20)
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. (2006) (20)
The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. (2017) (20)
S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer. (2011) (19)
Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma (2014) (19)
Impact of tumor sequencing on the use of anticancer drugs (2014) (19)
Prevention and management of major side effects of targeted agents in breast cancer. (2012) (18)
PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC). (2014) (18)
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma (2019) (18)
Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. (2016) (18)
The pipeline of new anticancer agents for breast cancer treatment in 2003. (2003) (18)
Phase I–II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) (1999) (18)
Remaining controversies in the upfront management of advanced ovarian cancer (2004) (18)
The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. (2017) (17)
A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. (2004) (17)
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer (2019) (17)
Molecular profiling of a tumor of unknown origin. (2006) (17)
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors (2014) (16)
Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer. (2009) (16)
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. (2008) (16)
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies (2011) (16)
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2013) (16)
Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives. (2012) (16)
New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective (2004) (16)
Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? (2009) (16)
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer (2016) (16)
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies (1998) (16)
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer (2017) (15)
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma (2008) (15)
Will the dark sky over advanced renal cell carcinoma soon become brighter? (2005) (15)
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma (2018) (15)
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma (2020) (15)
Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors. (2017) (15)
Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer (2017) (15)
Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients (2019) (15)
Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics. (2020) (15)
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies) (2006) (14)
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. (2012) (14)
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours (2019) (14)
Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors. (2009) (14)
A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. (2007) (14)
13PStage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) (2015) (14)
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial (2017) (14)
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors (2021) (14)
A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. (2013) (14)
Pseudotumor cerebri in renal transplant recipients: a diagnostic challenge. (1997) (14)
Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. (2021) (13)
A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors. (2015) (13)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours (2015) (13)
New therapeutic developments in renal cell cancer. (2009) (13)
RTK Inhibitors in Melanoma: From Bench to Bedside (2021) (13)
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers (2004) (13)
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule (1999) (13)
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms (2020) (13)
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors (2020) (13)
Are virus-induced cancers more sensitive to checkpoint inhibitors? (2016) (13)
State-of-the-art chemotherapy for advanced breast cancer. (2000) (13)
b-Sitosterol activates Fas signaling in human breast cancer cells (2007) (13)
Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 (2019) (13)
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy (2020) (13)
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). (2014) (12)
604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial (2012) (12)
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. (2020) (12)
1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) (2015) (12)
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study. (2018) (12)
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics (2021) (12)
347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC) (1995) (12)
Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research (2021) (12)
Does clinical and radiological response predict complete tumor control in N2–N3 squamous cell head and neck cancer after non-operative management of the neck? (2006) (12)
A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies. (2014) (12)
Recurrent thyroid cancer: a molecular-based therapeutic breakthrough (2011) (12)
Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study. (2018) (12)
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. (2002) (12)
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. (2003) (12)
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study (1998) (11)
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. (2012) (11)
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. (1996) (11)
333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985 (2015) (11)
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. (2017) (11)
Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer. (2009) (11)
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. (2022) (11)
Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study (2008) (11)
Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review (2014) (11)
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors (2016) (11)
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology (2021) (10)
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics (2019) (10)
Primary small-cell carcinoma of the pancreas: An extensive review of the literature with emphasis on therapy and prognosis (2008) (10)
Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy (2010) (10)
Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. (2020) (10)
Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy. (2017) (10)
Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. (2016) (10)
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). (2014) (10)
Testicular germ cell tumor: Short and long-term side effects of treatment among survivors. (2016) (10)
36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours (2008) (10)
Current-day precision oncology: from cancer prevention, screening, drug development, and treatment – have we fallen short of the promise? (2016) (10)
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next? (2011) (10)
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort. (2018) (10)
Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors. (2013) (9)
616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma (2012) (9)
Predictive factors for cancer-associated thrombosis in a large retrospective single-center study (2019) (9)
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion (2019) (9)
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO) (2019) (9)
Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: A promising anti-tumor agent (2002) (9)
EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). (2016) (9)
Faculty Opinions recommendation of MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2019) (9)
Breast cancer, locally advanced and metastatic (2012) (9)
397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC) (2010) (9)
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. (2003) (9)
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies* (2007) (8)
Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. (2010) (8)
NT-23PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG) (2014) (8)
Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). (2011) (8)
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment (2021) (8)
Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. (2011) (8)
Novel therapeutics in breast cancer—Looking to the future (2009) (8)
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial. (2011) (8)
Clinical development of new formulations of cytotoxics in solid tumors (2012) (8)
A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors. (2018) (8)
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors (2015) (8)
Phase I clinical and pharmacology study of the novel epothilone analog BMS-247550 given weekly in patients advanced solid tumors (2001) (8)
Novel mechanisms and approaches in the medical therapy of solid cancers. (2015) (8)
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer (2021) (8)
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT). (2015) (8)
Anticancer drug development: moving away from the old habits. (2014) (8)
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (2020) (8)
Salivary glands carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors (2006) (7)
Targeted therapy for breast cancer in older patients. (2020) (7)
381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors (2004) (7)
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer (2021) (7)
Mitomycin C and Vinblastine in combination with Amifostine in metastatic breast cancer (1997) (7)
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial (2020) (7)
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. (2002) (7)
Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. (2010) (7)
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. (2021) (7)
Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 (2021) (7)
A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors (2004) (7)
Precision oncology: as much expectations as limitations (2018) (7)
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. (2013) (7)
First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. (2016) (7)
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity (2020) (7)
Pharmacokinetics of Tipifarnib After Oral and Intravenous Administration in Subjects With Advanced Cancer (2006) (7)
Rare side-effects of checkpoint inhibitors (2016) (7)
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. (2002) (7)
Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents. (2000) (7)
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. (2002) (7)
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors (2009) (7)
Keynote comment: reimbursement for molecularly targeted anticancer agents. (2006) (7)
Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients (2016) (7)
Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. (2011) (6)
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors (2022) (6)
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy – current evidence and future trends (2010) (6)
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. (2022) (6)
600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors (2012) (6)
EORTC 10968; Phase I study of CaelyxTM at a six week interval in patients with metastatic breast cancer (1998) (6)
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) (2021) (6)
Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial). (2018) (6)
Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. (2019) (6)
New generations of targeted therapies fighting the resistance in solid tumors (2015) (6)
Head and neck cancer emerging strategies: advances and new challenges. (2009) (6)
Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function (2014) (6)
Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. (2015) (6)
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy (2003) (6)
Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development (2013) (6)
Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature (2014) (6)
Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC). (2015) (6)
Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer (2019) (6)
Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). (2011) (6)
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study (2017) (6)
Treatment of recurrent thyroid cancers--is there a light in the horizon? (2008) (6)
Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors (2012) (6)
Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate (2019) (6)
Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) (2015) (6)
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). (2014) (6)
Non-Infectious Pneumonitis (NIP) in Breast Cancer (BC) Patients (Pts) Treated with Everolimus (Afinitor™) Containing Therapy: Analysis of Five Studies. (2009) (6)
Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors (2016) (5)
Abstract P6-12-02: SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer (2017) (5)
Abstract P3-14-04: Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+ Metastatic Breast Cancer (2010) (5)
Faculty Opinions recommendation of Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. (2019) (5)
Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors (2004) (5)
LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study. (2017) (5)
Prevention of neutropenia-related events in elderly patients with hematological cancer (2011) (5)
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2021) (5)
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (5)
Long-term survival in pituitary metastasis from breast cancer. (2006) (5)
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. (2019) (5)
Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009 (2008) (5)
A paradigm shift in early drug development: individualizing to more patient benefit (2012) (5)
Adjuvant and neoadjuvant chemotherapy regimens in breast cancer: summary from the BSMO breast cancer task force meeting (2014) (5)
Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP) (2013) (5)
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study. (2013) (5)
Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria (2001) (5)
A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors (2001) (5)
Phase II study of CP-4126, a gemcitabine-lipid conjugate, in patients with advanced pancreatic cancer. (2010) (5)
Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. (2011) (5)
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial (2016) (5)
Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value (2021) (5)
Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC) (2010) (5)
Abstract P3-09-06: Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort (2020) (4)
Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC) (2013) (4)
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study (2022) (4)
A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers. (2018) (4)
A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. (2006) (4)
Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer (2013) (4)
Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies (2019) (4)
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. (2016) (4)
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis (2022) (4)
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (4)
Analyses of the rationale and implementation of research biopsies in oncology clinical trials at a tertiary cancer center. (2021) (4)
Abstract P6-11-01: Significant Efficacy in a Phase 2 Study of NKTR-102, a Novel Polymer Conjugate of Irinotecan, in Patients with Pre-Treated Metastatic Breast Cancer (MBC) (2010) (4)
Second primary cancers in head and neck cancer patients: a challenging entity. (2012) (4)
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis (2022) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. (2004) (4)
Palifermin and chemotherapy-induced oral mucositis. (2005) (4)
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. (2004) (4)
A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. (2009) (4)
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC). (2013) (4)
Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer (2002) (4)
Ovarian cancer: state of the art and future directions. (2004) (4)
Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers. (2005) (4)
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. (2022) (4)
Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives. (2019) (4)
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. (2017) (4)
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors (2020) (4)
[Development of new antineoplastic agents: 10 years of active clinical research marked by the evolution of treatment, from an empirical to a rational approach]. (2001) (4)
Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials (2020) (4)
[Therapeutic consequences of molecular biology advances in oncology]. (2009) (4)
Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival (2013) (4)
5018 Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC) (2009) (4)
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus (2019) (4)
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma (2022) (4)
BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. (2009) (4)
Stratified medicine: a call for action (2013) (4)
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. (2022) (4)
Breast cancer therapies in development. A review of their pharmacology and clinical potential. (1997) (4)
Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases. (2018) (4)
An integrated approach for tailored treatment in breast cancer. (2005) (4)
Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. (2011) (4)
Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen. (2009) (4)
Clinical trial design limitations in head and neck squamous cell carcinomas (2007) (4)
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer (2020) (4)
426 Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours (2010) (3)
Abstract P1-17-03: Abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer (2018) (3)
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer (2013) (3)
Neurological disorders in renal transplant recipients. (1998) (3)
The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck. (2007) (3)
Faculty Opinions recommendation of KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). (2019) (3)
Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis (2018) (3)
Metabolic disorders associated with the use of targeted cancer therapies (2015) (3)
Phase II study of E 7070 in patients with metastatic melanoma (2004) (3)
INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY (2003) (3)
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit (2021) (3)
The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation (2016) (3)
Abstract P1-12-08: Quality of Life in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes who Received Eribulin Mesylate or Capecitabine in a Phase III, Open-label, Randomized Study (2012) (3)
[Gemcitabine: a new chemotherapy agent for solid cancers]. (1997) (3)
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours (2021) (3)
Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. (2009) (3)
Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis. (2021) (3)
A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2* (2006) (3)
Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer (2015) (3)
Management of advanced head and neck squamous cell carcinoma in elderly patients. (2006) (3)
Advances in chemical pharmacotherapy to manage advanced breast cancer (2017) (3)
97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (2003) (3)
Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors? (2016) (3)
Pharmacokinetics (PK) of free and total paclitaxel after equal doses of paclitaxel injectable emulsion and paclitaxel injection (2005) (3)
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial. (2016) (3)
Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results (2020) (3)
Latent left ventricular outflow tract obstruction in Takotsubo cardiomyopathy. (2018) (3)
A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. (2012) (3)
First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies. (2021) (3)
A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer. (2014) (3)
528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours (2015) (3)
Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301 (2013) (3)
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). (2013) (3)
Abstract CT134: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of a NKG2D-based CAR-T therapy CYAD-01, in patients with unresectable liver metastases from colorectal cancer (2018) (3)
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience (2021) (3)
Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. (2021) (2)
101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc) (2012) (2)
538P Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) (2021) (2)
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies (2015) (2)
PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors. (2018) (2)
Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumors. (2010) (2)
P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose (2019) (2)
New Biological approaches to the treatment of cancer with a focus on breast cancer (2000) (2)
Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer. (2014) (2)
432 Phase Ib study of plitidepsin with bevacizumab in refractory solid tumor patients (pts) (2010) (2)
Docetaxel in the treatment of breast cancer: Current status, ongoing trials and future directions (1996) (2)
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers (2022) (2)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. (1997) (2)
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey (2021) (2)
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study (2014) (2)
How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice? (2019) (2)
Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter? (2005) (2)
Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases (2015) (2)
[Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis]. (2018) (2)
Faculty Opinions recommendation of Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. (2019) (2)
Lack of interference of S9788 with the pharmacokinetic of adriamycin (1995) (2)
Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize. (2019) (2)
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. (2020) (2)
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC). (2022) (2)
659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC) (2021) (2)
Extra-osseous Ewing sarcoma of the thyroid gland mimicking a hemorrhagic cyst of Hashimoto thyroiditis (2017) (2)
Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2015) (2)
Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors (2010) (2)
Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer (2016) (2)
New horizons in early drugs development in solid cancers (2021) (2)
Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study (1998) (2)
A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors (1992) (2)
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC). (2013) (2)
Faculty Opinions recommendation of Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC). (2019) (2)
374 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors (2010) (2)
Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors. (2010) (2)
How to emerge from the conservatism in clinical research methodology? (2017) (2)
Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue (2016) (2)
Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules (2005) (2)
Abstract CT123: A phase I study assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer (2018) (2)
Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers? (2015) (2)
Personalized Medicine, Genomic Profiling and Germline Mutations: Toward More Precise Decisions. (2019) (2)
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. (2012) (2)
Targeting molecular subtypes in solid cancers: successes and failures. (2020) (2)
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110. (2016) (2)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (2011) (2)
New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer. (2002) (2)
Phase I pharmacokinetic (PK) study of Taxotere (T) (RP56976, NSC628503) administered as a weekly infusion (1992) (2)
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). (2022) (2)
168PUpdated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts) (2017) (2)
Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III (2018) (1)
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel (2020) (1)
Faculty Opinions recommendation of PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). (2019) (1)
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients (2021) (1)
Gastrointestinal and Cardiovascular Safety Profiles of Neratinib Monotherapy in Patients with Advanced ErbB2-Positive Breast Cancer. (2009) (1)
Oral R101933, an inhibitor of MDR1 P-glyco-protein does not significantly after the pharmacokinetics and pharmacodynamics of Paclitaxel (1999) (1)
Trabectedin in sarcoma (2008) (1)
ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment. (2016) (1)
Low energy laser irradiation for the treatment of chemotherapy induced mucositis in bone marrow stem cell transplanted patients (2002) (1)
Phase I clinical study of Docetaxel (TXT) in combination with continuous infusion (CI) Fluorouracil (5-FU) in patients (pts) with advanced solid tumors (1996) (1)
Present and future breast cancer management-bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (1)
Faculty Opinions recommendation of MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. (2019) (1)
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]. (2008) (1)
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer (2021) (1)
[Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia]. (2007) (1)
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). (2021) (1)
Clinical trial design in advanced head and neck cancer: from past experiences to future perspectives (2012) (1)
AACR–NCI–EORTC International Conference 2009 (2010) (1)
5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy (2009) (1)
Faculty Opinions recommendation of TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. (2019) (1)
TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (2019) (1)
Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors. (2013) (1)
482PLURBINECTEDIN (PM01183) ON DAYS (D) 1 & 8 IN COMBINATION WITH CAPECITABINE (XEL) IN PATIENTS (PTS) WITH METASTATIC BREAST (MBC), COLORECTAL (CRC) OR PANCREATIC (PAC) CANCER. (2014) (1)
Targeted therapies for solid tumors: is the dream becoming a reality? (2006) (1)
First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metasta (2019) (1)
Abstract P3-10-03: Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the phase 3 BEACON study (2015) (1)
University of Groningen A Kinome RNAi Screen in Drosophila Identifies Novel Genes Interacting with Lgl, aPKC, and Crb Cell Polarity Genes in Epithelial Tissues (2017) (1)
Parametric imaging in PET/CT identifies non-responding lesions in head and neck cancer patients undergoing antiangiogenic treatment (2012) (1)
Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2012) (1)
Oxaliplatin and 5-fluorouracil in heavily pretreated patients with ovarian carcinoma: A well tolerated and efficient treatment (2007) (1)
Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy induced anemia (2010) (1)
Consensus text on the utilization of dexrazonane (Savene®) in anthracycline extravasation (2008) (1)
346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover (1995) (1)
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status. (2014) (1)
Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. (2021) (1)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019) (1)
A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors (1999) (1)
MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders (2021) (1)
Is tailored adjuvant treatment for colon cancer possible? (2010) (1)
Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review. (2020) (1)
Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. (2017) (1)
Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature. (2014) (1)
254 cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines (2010) (1)
Faculty Opinions recommendation of Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. (2019) (1)
P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC). (2011) (1)
[Topical photodynamic therapy in cutaneous oncology]. (2004) (1)
Abstract P2-13-05: Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC) (2022) (1)
98 POSTER A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors (2006) (1)
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives (2022) (1)
Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC) (2021) (1)
Final results from an open-label, randomised, phase II study of adecatumumab (MT201), a fully human anti-EpCAM antibody, in patients with metastatic breast cancer (2007) (1)
641 POSTER Effecacy and prediction of response to the new oral taxane DJ-927 in anthacycline pre-treated advanced breast cancer (ABC) (2006) (1)
Dose-seeking phase I trials (DSP1T) for currently approved molecular-targeted therapies (MTT): We are still far from using appropriate designs. (2014) (1)
A phase I, clinical and pharmacokinetic trial of Zarnestra (farnesyl transferase inhibitor, R115777) and docetaxel : a promising combination in patients with solid tumors (2001) (1)
Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma (2018) (1)
Abstract PD3-7: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer (2015) (1)
Prevalence and clinical impact of BRCA1/2 mutations in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). (2020) (1)
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. (2023) (1)
170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial (2020) (1)
Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force (2017) (1)
15 Microarray and validation analyses performed on melanoma metastases identify TYRP1 as a prognostic marker for both DMFS and OS (2010) (0)
How I treat endocrine-dependent metastatic breast cancer (2023) (0)
Cytokine Landscape in Central Nervous System Metastases (2022) (0)
Faculty Opinions recommendation of Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (0)
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer (2014) (0)
A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC? (2013) (0)
Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better (2016) (0)
Keloids and hypertrophic scars after surgery in cancer patients (2012) (0)
Faculty Opinions recommendation of Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. (2019) (0)
5091 Predictive role of Her-2 receptors on primary tumour in patients with liver metastases from breast cancer treated by surgery (2009) (0)
Faculty Opinions recommendation of Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2. (2019) (0)
99mTc-MIBI scintigraphies for the pharmacodynamic evaluation of R101933: A new inhibitor of the MDR-1 P-glycoprotein (PgP) (2000) (0)
A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy (2017) (0)
Faculty Opinions recommendation of Phase III study of taselisib (GDC-0032) + fulvestrant (FULV)v FULV in patients (pts) with estrogen receptor (ER)-positive,PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (2019) (0)
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities (2021) (0)
Abstract CN09-01: Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers (2019) (0)
The dynamics between neo-adjuvant treatment and immune responses in human breast cancer (2019) (0)
588P Analysis and adherence to the ASCO recommendations for research biopsies and archival tissue requirements in clinical trials conducted at Institut Jules Bordet (IJB) from 2015 to 2019 (2020) (0)
Abstract P1-07-11: Risk factors for the development of brain metastases (BM) in 506 patients with HER2-positive breast cancer (HER2+ BC): A single institutional retrospective analysis (2018) (0)
Abstract P1-03-02: Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies (2023) (0)
Concomitant chemo-radiotherapy as standard therapy in limited-stage small-cell oesophageal cancer: a summary of 3 clinical cases and review of the literature. (2008) (0)
418 Phase I, clinical, pharmacokinetic and schedule dependency study of the aurora kinase inhibitor AS703569 combined with gemcitabine in patients with solid tumors (2010) (0)
Abstract 3891: Tackling the obstacles facing the implementation of a molecular screening program in an early drug development unit: The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions - feasibility (Precision-f) (2015) (0)
The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma (2023) (0)
Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (2013) (0)
Clinical and pharmacoklnetic evaluation of the new blsnaphtalamlde LU 79553 administered every 21 days in patients with solid tumors: An EORTC/ECSG study (1997) (0)
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. (2022) (0)
Incidental finding of solitary fibrous tumor of male breast: case report and review of literature (2022) (0)
on behalf of EORTC-IDBBC: A fruitful European collaboration in new drug development for breast cancer (1996) (0)
Faculty Opinions recommendation of Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. (2019) (0)
Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation (2016) (0)
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions (2023) (0)
Faculty Opinions recommendation of Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. (2019) (0)
Abstract P6-15-09: Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study (2018) (0)
O188 Evaluation of outcomes in patients (pts) with head and neck squamous cell carcinoma (HNSCC) diagnosed with a second primary lung cancer (SPLC): a retrospective study (2007) (0)
' s response to reviews Title : The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia : an expert survey in breast cancer and non-Hodgkin ' s lymphoma (2010) (0)
[Cardiac metastase of a soft tissue sarcoma: a case report and a review of the literature]. (2014) (0)
Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced melanoma (2019) (0)
MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics (2021) (0)
Foreword for the edition of Treatment Strategies (2014) (0)
Pharmacokinetic phase I study of Caelyx in metastatic breast cancer patients (2001) (0)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration (1998) (0)
Abstract PS9-06: Adherence to and patient satisfaction with the combination therapy of exemestane and everolimus in postmenopausal women with HR+ HER2- advanced breast cancer: Results from the IPSOC-mamma study (2021) (0)
Intracardiac Metastasis from Epitheloid Sarcoma: Rare Localization and Difficult Management (2014) (0)
Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis. (2022) (0)
Faculty Opinions recommendation of Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 random (2019) (0)
Drugs prescribed for elderly oncologic patients hospitalized in the geriatric oncology unit of Institut Jules Bordet: Polypharmacy and impact of clinical pharmacist (2012) (0)
Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients withAdvancedBreastCancerafterTreatmentwith (2018) (0)
IIIA.2 New therapeutic developments in RCC (2007) (0)
Abstract 4618: Biomarkers of functionally active tertiary lymphoid structures in human breast cancer (2023) (0)
Abstract 2045: Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer (2022) (0)
[Kidney cancer: from biology to clinical medicine]. (2006) (0)
Phase I a nd P harmacokinetic S tudy o f t he O ral F arnesyl Transferase I nhibitor S CH 6 6336 G iven T wice D aily t o Patients W ith A dvanced S olid T umors (2001) (0)
Pharmacokinetic and pharmacodynamic relationships of copanlisib in patients with non-Hodgkin lymphoma and advanced solid tumors (2018) (0)
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer (2022) (0)
From Landmarks of Cancer to Targeted Therapies: Lessons Learnt and Perspectives (2012) (0)
Agents other than taxanes in active development for the treatment of breast cancer (1998) (0)
Intravitreal methotrexate in vemurafenib-induced uveitis. (2023) (0)
mTor inhibition in RCC: proof of concept, clinical use, and future directions (2011) (0)
Quality of life (QoL) and content validity in objective tumor response. (2013) (0)
Unexpected pleural changes observed in patients treated with Taxotere (RP 56976) : A new drug toxicity ? (1992) (0)
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment (2019) (0)
The role of Caelyx in metastatic breast cancer (2008) (0)
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel : retrospective analysis of EORTC24971 study (2015) (0)
251 Lessons learnt of 20 years of targeted therapies (2010) (0)
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2022) (0)
Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients (2019) (0)
Abstract PS17-21: Characterization of the immune microenvironment in ductal carcinomain situof the breast (2021) (0)
[Therapeutic management of malignant paragangliomas: an illustrative case and literature review]. (2019) (0)
Faculty Opinions recommendation of Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing. (2019) (0)
TCT-147 High wattage electronic cigarette vaping after coronary stenting induces arterial hypoxemia: a randomized clinical trial (2018) (0)
P809Effects of air temperature and pollution on Takotsubo cardiomyopathy (2019) (0)
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110 (2016) (0)
An economic approach of metastatic renal cell carcinoma (mRCC) in Belgium (2008) (0)
Whole body PET(CT) with FDG for treatment monitoring of patients with bone metastatic breast cancer (2008) (0)
153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials (2020) (0)
Abstract OT1-08-02: TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242) (2020) (0)
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2013) (0)
The dosing, schedule and route of chemotherapy in gynaecological cancers (2004) (0)
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study (2014) (0)
3604 AVOID: antiemetics for chemotherapy induced nausea and vomiting (CINV): a retrospectIve descriptive study, describing the use of aprepitant in Belgium (2009) (0)
Abstract 1612: Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat (2014) (0)
Differential Expression of the Na+/I- Symporter by Endocrine Receptor Status: A Potential New Therapeutic Target in Estrogen Receptor Negative High Grade Breast Cancers (2015) (0)
Echocardiographic demonstration of a thrombus straddling the patent foramen ovale and pulmonary embolism. (2018) (0)
Abstract CT530: Multiorgan metabolic imaging response assessment of abemaciclib (MiMe-A): Oncodistinct 002 (2022) (0)
Abstract 3962: Circulating tumor DNA (ctDNA) as an alternative to tumor biopsies for precision oncology: The Jules Bordet Institute experience (2016) (0)
Cytoprotection of Amifostine from radiochemotherapy and radioiodine therapy in head and neck cancer patients: strong signs of efficacy but not yet a standard treatment (1999) (0)
148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO) (2020) (0)
A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors. (2018) (0)
[New trends in the management of common solid malignant tumors]. (2005) (0)
How do cancer centres communicate clinical trials opportunities to patients on their websites (2017) (0)
Faculty Opinions recommendation of Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. (2019) (0)
Bladder metastasis from breast cancer : a case report and systematic literature review (2019) (0)
Improving the management of head and neck cancers: dream or reality? (2004) (0)
Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial. (2018) (0)
190 Newer cytotoxics in breast cancer – are there any and are they still needed? (2009) (0)
Angiogenesis inhibitors: a breakthrough in the treatment of solid cancers (2004) (0)
IIIA.3 The medical treatment of metastatic renal cell in the elderly: position paper of a SIOG Taskforce (2007) (0)
Molecular oncology: what is needed to speed access to innovative therapies in clinical research? (2022) (0)
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance (2022) (0)
Changing the clinical picture of challenging tumors: tales becoming reality? (2009) (0)
Relapsing ovarian cancer: selection of the therapeutic agent (2003) (0)
Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer. (2018) (0)
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110]. (2022) (0)
Phase I dose-escalation study of an oral administration of the pan-histonedeacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors. (2014) (0)
PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. (2023) (0)
A phase I study of Lonafarnib, a farnesyl transferase inhibitor in combination with herceptin plus paclitaxel in Her 2 / neu overexpressing breast cancer (2007) (0)
Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials (2015) (0)
EORTC 10941; Final results of a phase II study of liarozole fumarate in patients with metastatic breast cancer (1998) (0)
[Multiple neoplasms: etiological problems and possibilities for prevention]. (1992) (0)
BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006). (2021) (0)
159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts) (2020) (0)
A critical review of cutaneous toxicity of anticancer treatments (2008) (0)
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients (2017) (0)
181P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from a pooled analysis of two phase III studies (2022) (0)
Handbook of skin care in cancer patients (2012) (0)
Management of HER-2/neu-positive metastatic breast cancer (2008) (0)
Contents Volume 16, 1998 (2004) (0)
344P Clinical outcomes of platinum-based polichemotherapy in patients with advanced breast cancer: A 10-year single institutional experience (2020) (0)
Breast Cancer Therapies in Development (1997) (0)
SP-0207 INCIDENTS IN MEDICAL ONCOLOGY: MANAGEMENT AND CLINICAL IMPACT (2012) (0)
[Re: innovative therapeutic approaches in melanoma]. (2004) (0)
Tackling the challenges of brain metastases in solid tumors. (2018) (0)
ASCO 2008 Main Highlights (2008) (0)
Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM) (2016) (0)
Erratum (1855) (0)
Docetaxel (D) in combination with amifostine (A) in metastatic breast cancer (MBC): A feasibility and pharmacoklnetlc study of the EORTC-investigational drug branch for breast cancer (IDBBC) (1997) (0)
Molecular profiling as a strategy to propectively identify primary solid tumours in metastatic cancer patients (2010) (0)
Cancer du rein: De la biologie à la clinique (2006) (0)
Activation of the tumour suppressor PTEN as an alternative explanation for Trastuzumab’s mechanism of action (2005) (0)
Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas (2018) (0)
87 INVITED How to Optimise Strategies for Clinical Development of Combinations Based on Targeted Agents (2011) (0)
P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC. (2011) (0)
Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis (2016) (0)
Cisplatin/Epinephrine injectable gel: (a viewpoint) (2001) (0)
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2022) (0)
New drugs and new strategies for women with breast cancer (1997) (0)
Combined ipsilateral treatment of cervical lymph nodes metastases from an unknown primary. (2008) (0)
O82 Induction chemotherapy with Cisplatin and 5-Fluorouracil followed by neck dissection and chemoradiotherapy in the treatment of locoregionally advanced resectable cancers of the larynx and the harynx: results of single center study of 27 patients (2007) (0)
393PEFFICACY OF ERIBULIN IN A SECOND-LINE OR LATER SETTING IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): A POOLED ANALYSIS. (2014) (0)
Faculty Opinions recommendation of Palbociclib and letrozole in advanced breast cancer. (2019) (0)
Faculty Opinions recommendation of Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. (2019) (0)
Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgery. (2020) (0)
Antitumour effect of eighth-line gefitinib (‘Iressa’, ZD1839) in a heavily pretreated patient with adenocarcinoma of unknown primary origin (probably pulmonary) (2003) (0)
Anti-Cancer Drugs 2008 Author Index to Volume 19. (2008) (0)
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512 (2020) (0)
IIIA.2 Molecular-targeted therapies for elderly patients with breast cancer (2006) (0)
Abstract P1-13-02: Early change in topoisomerase 1 (Top1) positive circulating tumor cells (CTCs) is associated with overall survival (OS) in patients with advanced breast cancer after treatment with etirinotecan pegol (2016) (0)
Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines (2016) (0)
Faculty Opinions recommendation of Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. (2019) (0)
The Changing Clinical Research Pathway (2019) (0)
Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer (2022) (0)
Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial. (2018) (0)
Faculty Opinions recommendation of Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. (2019) (0)
A Global Perspective on Cooperation (2019) (0)
Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2015) (0)
Highly reduced incidence of new breast cancer metastases during treatment with adecatumumab appears to be the major factor for longer time to tumor progression in patients with high-level EpCAM expression (2007) (0)
Faculty Opinions recommendation of Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2019) (0)
LTX‐315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study (2017) (0)
Fulvestrant in heavily pretreated patients with advanced breast cancer: A Belgium cooperative study. (2006) (0)
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. (2023) (0)
State of the art of the management of metastatic breast cancer (MBC) (2002) (0)
Abstract P2-01-06: Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse (2022) (0)
A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (2015) (0)
1137 Implementation of new biological knowledge into cancer management (2003) (0)
High wattage e-cigarette vaping induces arterial hypoxemia and tissue hypoxia in tobacco smokers suffering from coronary artery disease: A RCT (2019) (0)
1826P Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: A global survey (2021) (0)
Abstract P1-21-03: Efficacy of tyrosine kinase inhibitors (TKI) in the treatment of patients with HER2-positive (HER2+) breast cancer with or without brain metastases: A systematic review and meta-analysis (2022) (0)
Faculty Opinions recommendation of Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. (2019) (0)
A phase I study of a prolonged schedule of temozolimide (Temodal (R)) plus liposomal doxorubicin (Caelyx (R)) in advanced solid cancers: Final results of a promising combination (2002) (0)
Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue (2016) (0)
Phase II trial with hormono-chemotherapy combining high-dose tamoxifen (HD-TAM), cisplatin (DDP) and fotemustine in metastasic malignant melanoma (MMM): Pilot study evaluation (1992) (0)
Abstract P1-10-05: Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01) (2020) (0)
Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study (2021) (0)
[Tolerablity of everolimus in clinical practice: a retrospective study]. (2020) (0)
Faculty Opinions recommendation of 16OFirst-line ribociclib + letrozole in HR+, HER2– ABC: Efficacy by baseline tumor markers. (2019) (0)
Controversial issues in managing locally advanced head and neck cancers (2008) (0)
41P Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials (2020) (0)
Letter of Welcome (2010) (0)
Faculty Opinions recommendation of Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. (2019) (0)
259P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies (2022) (0)
Cisplatin/Epinephrine Injectable Gel (2001) (0)
A phase I dose-ﬁnding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours (2006) (0)
108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies (2014) (0)
Biographies of invited faculty (2007) (0)
F24 Metastatic renal cell cancer: SIOG position paper (2009) (0)
Faculty Opinions recommendation of Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy. (2019) (0)
[Supportive care in cancer: concepts, achievements and challenges]. (2008) (0)
Abstract CT108: A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426) (2017) (0)
604 Farnesoid X receptor overexpression predicts breast cancer bone metastases through a Runx2-dependent mechanism (2010) (0)
[Therapeutic update on cancer of the breast]. (2000) (0)
Salvage surgery after failure of non surgical therapy for head and neck cancer (2007) (0)
Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer (2013) (0)
A Rare Case of Prostatic Extra Gonadal Germ Cell Tumor in a Young Adult: Review of the Literature (2016) (0)
“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy (2015) (0)
Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials” (2020) (0)
Could the D5 antigen replace estrogen and progesterone receptors (ER & PGR) as a marker of hormone dependency and a prognostic factor in early breast cancer (BC)? (1990) (0)
Rare Features of Dermatomyositis in a Patient with Ovarian Cancer. (2020) (0)
Oncology in Belgium: a global approach where research and clinic are joining. (2008) (0)
Influence of the cytoprotective agent Amifostine on toxicity and pharmacokinetics (PK) of Docetaxel (D) in metastatic breast cancer (MBC): A feasibility study of the EORTC-Investigational Drug Branch for Breast Cancer (IDBBC) (1998) (0)
Challenges and Threats (2019) (0)
Practical guide to chemotherapy and hormonal therapy administration for physicians and nurses (1999) (0)
EP113/#78 Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer (2022) (0)
Gene Expression and Proteomic Analysis to Identify Predictive Biomarkers of Response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept Study Evaluating First-Line Ganetespib Monotherapy in Women with Metastatic HER2 Positive or Triple Negative Breast Cancer (TNBC) (2014) (0)
Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints. (2013) (0)
Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology (2017) (0)
Promising Immuno-Oncology Treatments Beyond the 2018 (2019) (0)
Design and performance of clinical trials in head and neck cancer. (2010) (0)
00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS (2005) (0)
Abstract 3367: Massbalance, excretion and metabolism of [14C]-Pralatrexate (PDX) incancer patients in a phase I trial. (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ahmad Awada?

Ahmad Awada is affiliated with the following schools:

Seoul National University
Université libre de Bruxelles
Université de Montréal
University of Cologne
University of Oxford
Paracelsus Medical University

Ahmad Awada's Academic­Influence.com Rankings

Why Is Ahmad Awada Influential?

Ahmad Awada's Published Works

Published Works

What Schools Are Affiliated With Ahmad Awada?

Ahmad Awada's AcademicInfluence.com Rankings